医薬品セクターにおいて徐放性製剤市場の到来と共に、薬物の送達に関連する問題に対する画期的解決策の探求が終わりました。過去数年間に、治療レジメンにおける新規かつ機構的なアプローチと、その後に続く徐放性製剤は、製薬業界で大きな評価をもたらしました。この市場は、患者の体内の薬物濃度を望ましい範囲内に維持することが大いに必要とされています。これに加えて、患者の体内に薬物を投与するために使用される材料の非毒性や生体適合性などの重要な利点も保証します。
目次
1. Introduction to Controlled Drug Delivery
1.1 Novel Drug Delivery Systems
1.2 Preamble to Controlled Drug Delivery
1.3 Drug Delivery Technology
1.4 Fundamentals of Controlled Delivery
1.5 Basis for Controlled Drug Delivery
1.6 Controlled Drug Delivery Mechanism of Action
2. Controlled Drug Delivery Classification
2.1 By Delivery Systems
2.2 By Technology
2.3 By Routes of Delivery
2.4 Material Based Approaches for Controlled Drug Delivery
3. Global Controlled Drug Market Overview & Recent Trends at Regional Level
3.1 US
3.2 Europe
3.3 Japan
4. Global Controlled Release Drug Clinical Pipeline Overview
4.1 By Phase
4.2 By Company
4.3 By Country/Region
4.4 By Drug Class
4.5 By Indication
5. Controlled Release Drugs for Alzheimer’s Disease - Pricing, Patent & Dosage Insight
5.1 Namzaric (Extended-Release)
5.2 Namenda XR (Extended - Release)
5.3 Razadyne ER (Extended - Release)
6. Controlled Release Drugs for Parkinson’s Disease - Pricing, Patent & Dosage Insight
6.1 Gocovri (Extended- Release)
6.2 Osmolex ER (Extended - Release)
7. Controlled Release Drugs for Schizophrenia - Pricing, Patent & Dosage Insight
7.1 Perseris (Extended - Release)
7.2 Invega (Extended - Release)
7.3 Invega Sustenna/Invega Trinza (Extended - Release)
7.4 Seroquel XR (Extended - Release)
7.5 Abilify Maintena (Extended - Release)
7.6 Aristada (Extended - Release)
8. Controlled Release Drugs for Chronic Pain - Pricing, Patent & Dosage Insight
8.1 Hysingla ER (Extended - Release)
8.2 Nucynta ER (Extended - Release)
8.3 Kadian (Extended - Release)
8.4 Xtampza ER (Extended - Release)
8.5 MS Contin (Extended - Release)
8.6 Embeda (Extended - Release)
9. Controlled Release Drugs for Multiple Sclerosis - Pricing, Patent & Dosage Insight
9.1 Ampyra (Extended - Release)
9.2 Tecfidera (Delayed - Release)
9.3 Rayos (Delayed - Release)
9.4 Vumerity (Delayed - Release)
10. Controlled Release Drugs for Diabetes Mellitus Type II - Pricing, Patent & Dosage Insight
10.1 Glumetza (Extended - Release)
10.2 Glucotrol XL (Extended - Release)
10.3 Fortamet (Extended - Release)
10.4 Glucophage XR (Extended - Release)
10.5 Bydureon (Extended - Release)
11. Controlled Release Drugs for Hypertension & Angina Pectoris - Pricing, Patent & Dosage Insight
11.1 Procardia XL (Extended - Release)
11.2 Toprol XL (Extended - Release)
11.3 Adalat CC (Extended - Release)
11.4 Verelan PM (Extended - Release)
11.5 Plendil (Extended - Release)
11.6 Cardizem LA (Extended - Release)
12. Global Controlled Drug Clinical Trials Insight By Company, Indication & Phase
12.1 Research
12.2 Preclinical
12.3 Clinical
12.4 Phase-I
12.5 Phase-I/II
12.6 Phase-II
12.7 Phase-II/III
12.8 Phase-III
12.9 Preregistration
12.10 Registered
13. Marketed Controlled Drug Clinical Insight By Company & Indication
14. Global Controlled Drug Delivery Market Dynamics
14.1 Market Drivers
14.2 Challenges to be Resolved
15. Global Controlled Drug Delivery Market Future Outlook
16. Competitive Landscape
16.1 AbbVie
16.2 Adare Pharma Solutions
16.3 Assertio Therapeutics
16.4 Astellas Pharma
16.5 AstraZeneca
16.6 Bristol-Myers Squibb
16.7 GlaxoSmithKline
16.8 Pfizer
16.9 Sanofi
16.10 Supernus Pharmaceuticals
16.11 Takeda
